Does influenza vaccination improve pregnancy outcome? Methodological issues and research needs.

Abstract:

:Evidence that influenza vaccination during pregnancy is safe and effective at preventing influenza disease in women and their children through the first months of life is increasing. Several reports of reduced risk of adverse outcomes associated with influenza vaccination have generated interest in its potential for improving pregnancy outcome. Gavi, the Vaccine Alliance, estimates maternal influenza immunization programs in low-income countries would have a relatively modest impact on mortality compared to other new or under-utilized vaccines, however the impact would be substantially greater if reported vaccine effects on improved pregnancy outcomes were accurate. Here, we examine the available evidence and methodological issues bearing on the relationship between influenza vaccination and pregnancy outcome, particularly preterm birth and fetal growth restriction, and summarize research needs. Evidence for absence of harm associated with vaccination at a point in time is not symmetric with evidence of benefit, given the scenario in which vaccination reduces risk of influenza disease and, in turn, risk of adverse pregnancy outcome. The empirical evidence for vaccination preventing influenza in pregnant women is strong, but the evidence that influenza itself causes adverse pregnancy outcomes is inconsistent and limited in quality. Studies of vaccination and pregnancy outcome have produced mixed evidence of potential benefit but are limited in terms of influenza disease assessment and control of confounding, and their analytic methods often fail to fully address the longitudinal nature of pregnancy and influenza prevalence. We recommend making full use of results of randomized trials, re-analysis of existing observational studies to account for confounding and time-related factors, and quantitative assessment of the potential benefits of vaccination in improving pregnancy outcome, all of which should be informed by the collective engagement of experts in influenza, vaccines, and perinatal health.

journal_name

Vaccine

journal_title

Vaccine

authors

Savitz DA,Fell DB,Ortiz JR,Bhat N

doi

10.1016/j.vaccine.2015.08.041

subject

Has Abstract

pub_date

2015-11-25 00:00:00

pages

6430-5

issue

47

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(15)01168-8

journal_volume

33

pub_type

杂志文章,评审

相关文献

VACCINE文献大全
  • Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.

    abstract::This study investigates the safety, immunogenicity and efficacy of different pox-vector vaccines expressing the haemagglutinin of a highly pathogenic (HP) H5N1 avian influenza virus (AIV) (A/chicken/Indonesia/7/03) in pigs. Pigs were vaccinated twice, with a 4-week interval, with a fowlpox (TROVAC), a canarypox (ALVAC...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.02.006

    authors: Kyriakis CS,De Vleeschauwer A,Barbé F,Bublot M,Van Reeth K

    更新日期:2009-04-06 00:00:00

  • Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial.

    abstract::Sequential or co-administration of vaccines has potential to alter the immune response to any of the antigens. Existing literature suggests that prior immunisation of tetanus/diphtheria-containing vaccines can either enhance or suppress immune response to conjugate pneumococcal or meningococcal vaccines. We examined t...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2016.10.020

    authors: Tashani M,Alfelali M,Barasheed O,Alqahtani AS,Heron L,Wong M,Rashid H,Booy R

    更新日期:2016-11-21 00:00:00

  • Vaccination-induced HI antibody to influenza A(H1N1) viruses in poorly primed adults under circumstances of low antigenic drift.

    abstract::In Autumn 1990, trivalent split influenza virus vaccine containing A/Taiwan/1/86(H1N1) was used to immunize healthy female employees (n = 104). The 11-12 amino acid differences in the HA1 domain of virus haemagglutinin between A/Taiwan/1/86 and representative epidemic H1N1 strains in Finland in 1991 did not result in ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(93)90126-i

    authors: Pyhälä R,Kinnunen L,Kumpulainen V,Ikonen N,Kleemola M,Cantell K

    更新日期:1993-01-01 00:00:00

  • The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults.

    abstract::Intranasal live attenuated influenza vaccine (LAIV) has potential for self-administration (SA) by adults and adolescents, which could save time and cost in mass vaccination settings. Participants in a study of LAIV in adults (n=4561) selected either SA or health care provider (HCP) administration and were followed for...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2012.12.028

    authors: Ambrose CS,Wu X

    更新日期:2013-01-30 00:00:00

  • Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors.

    abstract::Human botulism is commonly associated with botulinum neurotoxin (BoNT) serotypes A, B, E and F. This suggests that the greatest need is for a tetravalent vaccine that provides protection against all four of these serotypes. In current study, we investigated the feasibility of generating several tetravalent vaccines th...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.03.046

    authors: Yu YZ,Guo JP,An HJ,Zhang SM,Wang S,Yu WY,Sun ZW

    更新日期:2013-05-07 00:00:00

  • Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform.

    abstract::The canarypox vaccine vector (ALVAC) technology has been used to develop and license several vaccines for companion animals and horses in the European Union and USA. ALVAC is a ubiquitous vector with high biosafety since it is non-replicative in mammalians, is genetically and physically stable, and able to induce both...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2006.11.066

    authors: Poulet H,Minke J,Pardo MC,Juillard V,Nordgren B,Audonnet JC

    更新日期:2007-07-26 00:00:00

  • Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms.

    abstract::Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a potent immune stimulant when administered with different vaccines. Optimal use of GM-CSF resides in its ability to act locally to stimulate the proliferation and maturation of professional antigen-presenting cells (APCs) (i.e., Langerhans' cells) at the in...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.11.060

    authors: Reali E,Canter D,Zeytin H,Schlom J,Greiner JW

    更新日期:2005-04-22 00:00:00

  • RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial.

    abstract:BACKGROUND:We report the first-in-concept human trial of the safety, tolerability and immunogenicity when a novel TLR 7/8/RIG I agonist RNA-based adjuvant, CV8102, was administered alone or mixed with fractional doses of a licensed rabies vaccine (Rabipur®) as model antigen. METHODS:The primary objective was to assess...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.02.024

    authors: Doener F,Hong HS,Meyer I,Tadjalli-Mehr K,Daehling A,Heidenreich R,Koch SD,Fotin-Mleczek M,Gnad-Vogt U

    更新日期:2019-03-22 00:00:00

  • Is freezing in the vaccine cold chain an ongoing issue? A literature review.

    abstract::Vaccine exposure to temperatures below recommended ranges in the cold chain may decrease vaccine potency of freeze-sensitive vaccines leading to a loss of vaccine investments and potentially places children at risk of contracting vaccine preventable illnesses. This literature review is an update to one previously publ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2016.09.070

    authors: Hanson CM,George AM,Sawadogo A,Schreiber B

    更新日期:2017-04-19 00:00:00

  • HIV vaccine candidates generate in vitro T cell response to putative epitopes in Chinese-origin rhesus macaques.

    abstract::The Indian rhesus macaque is the established animal model for HIV infection and vaccine research. Growing evidence suggests that the more readily available Chinese rhesus macaque may be a more relevant option. As increasing numbers of novel Chinese rhesus MHC alleles are reported, we decided to explore potential HIV v...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.12.117

    authors: Liao Q,Strong AJ,Liu Y,Liu Y,Meng P,Fu Y,Touzjian N,Shao Y,Zhao Z,Lu Y

    更新日期:2012-02-21 00:00:00

  • Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA).

    abstract::The Lister (Elstree) strain of vaccinia virus, used in Israel for vaccination against smallpox, was studied in tissue cultures and in a mouse model. The virus failed to reach the brain of the mice when inoculated intranasally at a dose of 500,000 plaque forming units, but was lethal for 50% of them, when injected intr...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.02.012

    authors: Abdalrhman I,Gurt I,Katz E

    更新日期:2006-05-08 00:00:00

  • Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine.

    abstract::Whole killed meningococci (Nm) and pertussis bacteria (Bp) were tested for mucosal immunogenicity and as mucosal adjuvants for an inactivated influenza virus vaccine given intranasally to unanaesthetized mice. Virus was given alone, or simply mixed with one of the bacterial preparations, in four doses at weekly interv...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(99)00442-9

    authors: Berstad AK,Andersen SR,Dalseg R,Dromtorp S,Holst J,Namork E,Wedege E,Haneberg B

    更新日期:2000-03-17 00:00:00

  • Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate.

    abstract::Chagas' disease is a major tropical disease for which a cure for chronic phase does not exist yet. Trypanosoma cruzi trans-sialidase (TS) seems to be involved in relevant processes such as infectivity, host survival and, very importantly, disease pathogenesis. In this study, we show that mice vaccinated with an engine...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.02.060

    authors: Fontanella GH,De Vusser K,Laroy W,Daurelio L,Nocito AL,Revelli S,Contreras R

    更新日期:2008-05-02 00:00:00

  • Hospital-based surveillance and molecular epidemiology of rotavirus infection in Taiwan, 2005-2007.

    abstract::To determine the distribution of rotavirus strains and facilitate vaccine policy decisions in Taiwan, active hospital-based gastroenteritis surveillance was conducted in three sentinel hospitals. From 1 January 2005 to 31 December 2007, a total of 3435 children less than 5 years old with gastroenteritis were enrolled....

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.08.090

    authors: Wu FT,Liang SY,Tsao KC,Huang CG,Lin CY,Lin JS,Su CY,Eng HL,Yang JY,Chen PJ,Yang CF

    更新日期:2009-11-20 00:00:00

  • Design and immunogenicity analysis of the combined vaccine against zoonotic hepatitis E and foot-and-mouth disease.

    abstract:AIM:Design and immunogenicity assessment of the combined vaccine candidate against zoonotic hepatitis E virus (HEV) and foot-and-mouth disease virus (FMDV). METHODS:Using the molecular cloning technology, we produced and purified 9 HEV ORF2-truncated proteins (HEV genotype 4). Then, we compared their thermal stability...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.09.036

    authors: Liu Z,Behloul N,Baha S,Wei W,Shi R,Meng J

    更新日期:2019-10-31 00:00:00

  • Development of a membrane adsorber based capture step for the purification of yellow fever virus.

    abstract::Yellow fever (YF) is an endemic disease in some tropical areas of South America and Africa that presents lethality rate between 20 and 50%. There is no specific treatment and to control this disease a highly effective live-attenuated egg based vaccine is widely used for travelers and residents of areas where YF is end...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.02.036

    authors: Pato TP,Souza MC,Silva AN,Pereira RC,Silva MV,Caride E,Gaspar LP,Freire MS,Castilho LR

    更新日期:2014-05-19 00:00:00

  • Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis.

    abstract::Pregnant goats were employed to assess unmarked deletion mutant vaccine candidates BMDeltaasp24, BMDeltacydBA, and BMDeltavirB2, as the target host species naturally infected with Brucella melitensis. Goats were assessed for the degree of pathology associated with the vaccine strains as well as the protective immunity...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.04.005

    authors: Kahl-McDonagh MM,Elzer PH,Hagius SD,Walker JV,Perry QL,Seabury CM,den Hartigh AB,Tsolis RM,Adams LG,Davis DS,Ficht TA

    更新日期:2006-06-12 00:00:00

  • Intradermal immunization improves protective efficacy of a novel TB vaccine candidate.

    abstract::We have developed the Mycobacterium tuberculosis (Mtb) fusion protein (ID83), which contains the three Mtb proteins Rv1813, Rv3620 and Rv2608. We evaluated the immunogenicity and protective efficacy of ID83 in combination with several emulsion-formulated toll-like receptor agonists. The ID83 subunit vaccines containin...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.03.018

    authors: Baldwin SL,Bertholet S,Kahn M,Zharkikh I,Ireton GC,Vedvick TS,Reed SG,Coler RN

    更新日期:2009-05-18 00:00:00

  • Protection of chickens from Newcastle disease by vaccination with a linear plasmid DNA expressing the F protein of Newcastle disease virus.

    abstract::To evaluate the usefulness of a DNA vaccine for chickens, we constructed a plasmid vector expressing the Newcastle disease virus F protein (NDV-F) under the control of the human cytomegalovirus immediate early enhancer and chicken beta-actin gene promoter. One-week-old chickens injected intramusculary with the circula...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(95)00254-x

    authors: Sakaguchi M,Nakamura H,Sonoda K,Hamada F,Hirai K

    更新日期:1996-06-01 00:00:00

  • Colostral transmission of BTV-8 antibodies from dairy cows six years after vaccination.

    abstract::Bluetongue virus (BTV) antibodies were analysed in 27 Swiss calves born in 2016 at the age of 16-19 days using competitive enzyme-linked-immunosorbent-assay (cELISA) and virus neutralization test (VNT) (animal trial permission number: 75684). Obligatory documentation proved that 15 of 27 dams were BTV-8 vaccinated onc...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.08.015

    authors: Ayrle H,Mevissen M,Kaske M,Vögtlin A,Fricker R,Hoffmann B,Büttner M,Marinovic Z,Walkenhorst M

    更新日期:2018-09-18 00:00:00

  • Comparative immunogenicity in children of mammalian cell-derived recombinant hepatitis B vaccine and plasma-derived hepatitis B vaccine.

    abstract::Three doses of hepatitis B vaccine were given at 2, 4 and 9 months of age to 220 Senegalese infants living in the Dakar area of Senegal. Half of the infants received 5 micrograms plasma-derived hepatitis B vaccine (Hevac B) and the remainder 20 micrograms mammalian cell-derived recombinant hepatitis B vaccine (GenHeva...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(92)90067-t

    authors: Coursaget P,Bringer L,Sarr G,Bourdil C,Fritzell B,Blondeau C,Yvonnet B,Chiron JP,Jeannée E,Guindo S

    更新日期:1992-01-01 00:00:00

  • Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.

    abstract:BACKGROUND:Each year a substantial number of Dutch elderly suffers from herpes zoster (HZ), caused by the reactivation of the varicella zoster virus (VZV). A potential complication of HZ is postherpetic neuralgia (PHN) which results in a prolonged loss of quality of life. A large randomized clinical trial, labelled the...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.12.067

    authors: de Boer PT,Pouwels KB,Cox JM,Hak E,Wilschut JC,Postma MJ

    更新日期:2013-02-18 00:00:00

  • Mumps disease in Beijing in the era of two-dose vaccination policy, 2005-2016.

    abstract:BACKGROUND:Since the introduction of mumps-containing vaccines (MuCV) in 1995 in Beijing, two-dose MuCV vaccination policy has been used, with the 1st and 2nd doses given at 18 months and 6 years of age, respectively. METHODS:Mumps epidemiology during 2005-2016 was described using surveillance data. Vaccine effectiven...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.03.074

    authors: Ma R,Lu L,Zhou T,Pan J,Chen M,Pang X

    更新日期:2018-05-03 00:00:00

  • Immunologic synergism with IL-2 and effects of cCHMIs on mRNA expression of IL-2 and IFN-gamma in chicken peripheral T lymphocyte.

    abstract::Two compound Chinese herbal medicinal ingredients (cCHMIs) were prepared, respectively, with epimedium polysaccharide plus propolis flavone (cCHMIs 1) and astragalus polysaccharide plus ginsenoside (cCHMIs 2). In animal immune experiment, Newcastle disease vaccine was mixed, respectively, with two cCHMIs and IL-2 to v...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.07.005

    authors: Wang D,Li X,Xu L,Hu Y,Zhang B,Liu J

    更新日期:2006-11-30 00:00:00

  • Association of HLA class II genes with clinical hyporesponsiveness to trivalent inactivated influenza vaccine in children.

    abstract:BACKGROUND:The primary prevention measure for influenza infection has been the use of influenza vaccines. However, even when the vaccine and circulating strains are well-matched, some healthy children do not respond to the vaccine, likely due to a genetic basis for immune hyporesponsiveness. The primary objective of th...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.12.026

    authors: Narwaney KJ,Glanz JM,Norris JM,Fingerlin TE,Hokanson JE,Rewers M,Hambidge SJ

    更新日期:2013-02-04 00:00:00

  • Homotopes affect primary and secondary antibody responses in poultry.

    abstract::Activation of the innate immune system by different homotopes may direct the subsequent specific immune response, and as a consequence may have significant implications on vaccination. In this study, effects of i.v. administered lipopolysaccharide (LPS), and lipoteichoic acid (LTA), respectively, and s.c. administered...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.11.037

    authors: Maldonado LM,Lammers A,Nieuwland MG,De Vries Reilingh G,Parmentier HK

    更新日期:2005-04-15 00:00:00

  • Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.

    abstract::A highly efficacious vaccine is required to counteract a threat of an avian influenza pandemic. Increasing the potency of vaccines by adjuvation is essential not only to overcome generally low immunogenicity of pandemic strains, but also to allow dose sparing and as such to make it feasible to satisfy huge global prod...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.04.071

    authors: Radosević K,Rodriguez A,Mintardjo R,Tax D,Bengtsson KL,Thompson C,Zambon M,Weverling GJ,Uytdehaag F,Goudsmit J

    更新日期:2008-07-04 00:00:00

  • Expression of HIV-1 envelope gene by recombinant avipox viruses.

    abstract::Recombinant canarypox (CP) and fowlpox (FP) viruses that contained two forms of the HIV-1 (SF2 strain) env gene were engineered and their expression analysed in chick, simian and human cells. These vectors can efficiently replicate in avian but not in mammalian cells, in which infection is abortive. The two forms, con...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(94)90180-5

    authors: Radaelli A,De Giuli Morghen C

    更新日期:1994-09-01 00:00:00

  • WHO Working Group on revision of the Manual of Laboratory Methods for Testing DTP Vaccines-Report of two meetings held on 20-21 July 2006 and 28-30 March 2007, Geneva, Switzerland.

    abstract::This report reflects the discussion and conclusions of a WHO group of experts from National Regulatory Authorities (NRAs), National Control Laboratories (NCLs), vaccine industries and other relevant institutions involved in standardization and control of diphtheria, tetanus and pertussis vaccines (DTP), held on 20-21 ...

    journal_title:Vaccine

    pub_type:

    doi:10.1016/j.vaccine.2008.02.013

    authors: Corbel MJ,Das RG,Lei D,Xing DK,Horiuchi Y,Dobbelaer R,WHO Working Group.

    更新日期:2008-04-07 00:00:00

  • Specific memory B cell response and participation of CD4+ central and effector memory T cells in mice immunized with liposome encapsulated recombinant NE protein based Hepatitis E vaccine candidate.

    abstract:BACKGROUND:Liposome encapsulated neutralizing epitope protein of Hepatitis E virus (HEV), rNEp, our Hepatitis E vaccine candidate, was shown to be immunogenic and safe in pregnant and non-pregnant mice and yielded sterilizing immunity in rhesus monkeys. METHODS:The current study in Balb/c mice assessed the levels and ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.10.046

    authors: Kulkarni SP,Thanapati S,Arankalle VA,Tripathy AS

    更新日期:2016-11-21 00:00:00